126.99USD-0.18%Mkt Cap: 25.79B $P/E: 16.21Today
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment o…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap25.79B $
Enterprise Value21.29B $
Revenue (TTM)5.82B $
Gross Profit4.77B $
Net Income (TTM)1.29B $
Revenue/Share29.36 USD
Last Price126.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.8K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS45337C1027
Valuation
P/E (Trailing)16.21
P/E (Forward)14.23
PEG30.60
EV/EBITDA10.96
EV/Revenue3.66
P/S4.43
P/B4.03
EPS (TTM)7.77
EPS (Forward)8.94
52W Range
81.0989% of range132.58
52W High132.58 USD
52W Low81.09 USD
Profitability
Gross Margin92.76%
Oper. Margin41.90%
EBITDA Margin33.38%
Profit Margin25.03%
ROE24.90%
ROA18.49%
Growth
Revenue Growth37.70%
Earnings Growth37.70%
Cash Flow & Leverage
Operating CF1.41B $
CapEx (TTM)83.87M $
FCF Margin20.29%
FCF Yield4.58%
Net Debt-4.50B $
Net Debt/EBITDA-2.32
Balance Sheet
Debt/Equity0.01
Current Ratio4.59
Quick Ratio4.31
Book Value/Sh31.57 USD
Cash/Share22.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateSep 1, 2000
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)126.04 USD
Upside (mean)-0.7%
Target Range86.00 USD – 155.00 USD
$86.00-0.7% to mean$155.00
# Analysts23
Ownership
Shares Out.202.70M
Float170.74M
Insiders1.84%
Institutions103.82%
Short Interest
Short Ratio5.3d
Short % Float8.62%
Short % Out.5.06%
Shares Short10.25M
Short (prev mo.)10.58M
Technical
SMA 50115.75 (+9.7%)
SMA 200103.52 (+22.7%)
Beta0.77
S&P 52W Chg18.16%
Avg Vol (30d)1.67M
Avg Vol (10d)1.27M
Technical Indicators
RSI (14)64.5
MACD2.7190
MACD Signal2.4805
MACD Hist.+0.2385
BB Upper129.16 USD
BB Middle121.69 USD
BB Lower114.22 USD
BB Width12.28%
ATR (14)3.851 USD
Vol Ratio (20d)0.64x